These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 23452163

  • 1. Gut microbiota and non-alcoholic fatty liver disease: new insights.
    Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K.
    Clin Microbiol Infect; 2013 Apr; 19(4):338-48. PubMed ID: 23452163
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The gut microbiota, obesity and insulin resistance.
    Shen J, Obin MS, Zhao L.
    Mol Aspects Med; 2013 Feb; 34(1):39-58. PubMed ID: 23159341
    [Abstract] [Full Text] [Related]

  • 7. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH, DiBaise JK, McClain CJ.
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD.
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [Abstract] [Full Text] [Related]

  • 10. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance.
    Parnell JA, Raman M, Rioux KP, Reimer RA.
    Liver Int; 2012 May; 32(5):701-11. PubMed ID: 22221818
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula.
    Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X.
    Syst Appl Microbiol; 2013 May; 36(3):188-96. PubMed ID: 23453736
    [Abstract] [Full Text] [Related]

  • 15. Non-alcoholic steatohepatitis: a microbiota-driven disease.
    Moschen AR, Kaser S, Tilg H.
    Trends Endocrinol Metab; 2013 Nov; 24(11):537-45. PubMed ID: 23827477
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R, Ma J, Li H.
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.